Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

Status:	Active, not recruiting
Conditions:	Gastrointestinal
Therapuetic Areas:	Gastroenterology
Healthy:	No
Age Range:	Any - 1
Updated:	3/24/2019
Start Date:	May 21, 2016
End Date:	August 2019

Phase 3 Study of Standard Lipid Therapy Versus Intravenous Fat Emulsion Minimization for the Prevention of Parenteral Nutrition-Associated Liver Disease

Parenteral nutrition-associated cholestasis (PNAC) and liver disease (PNALD) are associated
with significant morbidity and mortality in neonates and is felt to be exacerbated by
soybean-based lipid emulsions. Much research is currently being directed at identifying ways
to reduce this risk. Reduction of the dose of soybean-based lipid given as a component of
parenteral nutrition is one possible strategy. In this study we will compare standard dosing
of soybean-based lipid (up to 3/kg/day) with a minimized dose (1 g/kg/day) and evaluate for
the development of cholestasis and adequate growth between the two groups. Longterm followup
will include an assessment of neurodevelopmental outcomes at 12 and 24 months of age.

Funding source - FDA OOPD

Inclusion Criteria:

- neonates and infants who are at least 28 weeks corrected gestational age at the time
of enrollment who are parenteral nutrition (PN) naive

- current direct bilirubin <2 mg/dL

- any of the following conditions:

- meconium ileus and peritonitis

- gastroschisis

- omphalocele >4cm or with liver herniated outside of the abdominal cavity

- necrotizing enterocolitis requiring surgical intervention

- volvulus

- intestinal atresia with >50% bowel loss

Exclusion Criteria:

- weight <1 kg

- metabolic pathway defect which is associated with liver dysfunction in the neonatal
period, including: hereditary fructose intolerance, galactosemia due to transferase
deficiency and neonatal tyrosinemia, and/or disorder of lipid metabolism

- hepatic insufficiency as documented by either a biopsy with cirrhosis and/or marked
aberration in synthetic function

- renal failure

- primary or secondary liver disease, regardless of liver function (includes hepatitis)

- use of extracorporeal membrane oxygenation (ECMO)

- suspected congenital obstruction of the hepatobiliary tree

- documented active infection which may be communicable, including infections hepatitis
or HIV

- previous receipt of choleretic agents

- currently receiving phenobarbital or other barbiturates

- history of PNAC

- direct bilirubin >=2 mg/dL at time of enrollment

- congenital or acquired anomaly which will require major cardiovascular surgery

- major congenital or chromosomal anomaly

- hypoxic ischemic encephalopathy

- congenital defect of the brain

- major seizure disorder

We found this trial at

sites

University of Michigan

500 S State St
Ann Arbor, Michigan 48109

(734) 764-1817